Literature DB >> 11593393

Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer.

I A Steele1, R J Edmondson, J N Bulmer, B S Bolger, H Y Leung, B R Davies.   

Abstract

Epithelial ovarian cancers (EOCs) arise in the Ovarian Surface Epithelium (OSE). This tissue is a simple, poorly committed mesothelium which exhibits characteristics of epithelial and mesenchymal cells when grown in culture. In contrast, EOCs frequently exhibit properties of complex epithelial tissues of the female reproductive tract, such as oviductal, endometrial and cervical epithelia, and show induction of expression of epithelial markers such as E-cadherin. Fibroblast Growth Factor Receptor 2 isoform IIIb (FGF receptor 2-IIIb) is a spliced variant of FGF receptor 2 that binds the ligands FGF-1 and FGF-7 with high affinity, and is expressed exclusively by epithelial cells. We have studied the expression of FGF receptor 2-IIIb and its ligands in primary cultures of normal human OSE, EOC cell lines and snap frozen tissue from EOCs. Expression of FGF receptor 2-IIIb mRNA is undetectable in normal OSE, but is expressed in 16/20 (80%) of EOCs. FGFs 1 and 7 mRNAs are expressed in normal OSE, whilst only 4/20 (20%) and 12/20 (60%) of EOCs demonstrated expression for these ligands respectively. However, FGF-7 protein was detected in 70% (mean level=0.7 ng/ml) of ascitic fluids obtained from patients with EOC. FGFs 1 and 7 stimulate DNA synthesis in EOC cell lines that express FGF receptor 2-IIIb. Moreover, DNA synthesis in these cell lines can be partially blocked by blocking antisera to FGFs 1 and 7. It is suggested that induction of expression of FGF receptor 2-IIIb may play a role in the development of EOCs by rendering the OSE susceptible to paracrine and/or autocrine stimulation by its requisite FGF ligands.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11593393     DOI: 10.1038/sj.onc.1204755

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts.

Authors:  Wei-meng Zhao; Lihong Wang; Hangil Park; Sophea Chhim; Melanie Tanphanich; Masakazu Yashiro; K Jin Kim
Journal:  Clin Cancer Res       Date:  2010-07-29       Impact factor: 12.531

3.  Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.

Authors:  Claire Cole; Sin Lau; Alison Backen; Andrew Clamp; Graham Rushton; Caroline Dive; Cassandra Hodgkinson; Rhona McVey; Henry Kitchener; Gordon C Jayson
Journal:  Cancer Biol Ther       Date:  2010-09-04       Impact factor: 4.742

4.  FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway.

Authors:  Moitri Basu; Satinath Mukhopadhyay; Uttara Chatterjee; Sib Sankar Roy
Journal:  J Biol Chem       Date:  2013-11-19       Impact factor: 5.157

Review 5.  Wnt signaling in ovarian tumorigenesis.

Authors:  T A Gatcliffe; B J Monk; K Planutis; R F Holcombe
Journal:  Int J Gynecol Cancer       Date:  2007-11-06       Impact factor: 3.437

6.  Targets of fibroblast growth factor 1 (FGF-1) and FGF-2 signaling involved in the invasive and tumorigenic behavior of carcinoma cells.

Authors:  Clotilde Billottet; Nadia Elkhatib; Jean-Paul Thiery; Jacqueline Jouanneau
Journal:  Mol Biol Cell       Date:  2004-07-28       Impact factor: 4.138

7.  Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations.

Authors:  Margaret A Gates; Shelley S Tworoger; Kathryn L Terry; Immaculata De Vivo; David J Hunter; Susan E Hankinson; Daniel W Cramer
Journal:  Int J Cancer       Date:  2009-02-01       Impact factor: 7.396

8.  Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.

Authors:  Qing H Meng; Enping Xu; Michelle A T Hildebrandt; Dong Liang; Karen Lu; Yuanqing Ye; Elizabeth A Wagar; Xifeng Wu
Journal:  Clin Chem       Date:  2013-10-21       Impact factor: 8.327

9.  Interactions of adiponectin and lipopolysaccharide from Porphyromonas gingivalis on human oral epithelial cells.

Authors:  Dominik Kraus; Jochen Winter; Søren Jepsen; Andreas Jäger; Rainer Meyer; James Deschner
Journal:  PLoS One       Date:  2012-02-02       Impact factor: 3.240

10.  The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling.

Authors:  Silvia Zecchini; Lorenzo Bombardelli; Alessandra Decio; Marco Bianchi; Giovanni Mazzarol; Fabio Sanguineti; Giovanni Aletti; Luigi Maddaluno; Vladimir Berezin; Elisabeth Bock; Chiara Casadio; Giuseppe Viale; Nicoletta Colombo; Raffaella Giavazzi; Ugo Cavallaro
Journal:  EMBO Mol Med       Date:  2011-07-08       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.